SCHEMBL3370217

SCHEMBL3370217

Cc1ccc(S(=O)(=O)n2cc(C=O)cc2-c2ccc3c(c2)OCO3)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
TP53 P04637 1/20 0.45
PKM P14618 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CA12 O43570 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
ALDH1A1 P00352 4/20 0.42
TDP1 Q9NUW8 2/20 0.42
HSD17B10 Q99714 1/20 0.42
LMNA P02545 2/20 0.41
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PTGS2 P35354 6/20 0.41
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
PTGS1 P23219 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3367906 0.82 GLRA3 (0.41) MAPTSMN1; SMN2PKMMEN1KMT2A
SCHEMBL17520500 0.81 FYN (0.45) MAPTSMN1; SMN2TP53PKMMEN1
SCHEMBL1155931 0.79 KDM4E (0.46) MAPTSMN1; SMN2TP53CA12CA2
SCHEMBL1156049 0.79 LMNA (0.44) SMN1; SMN2PKMKMT2ALMNAPTGS2
SCHEMBL1156187 0.78 KDM4E (0.51) MAPTSMN1; SMN2CA2ALDH1A1LMNA
SCHEMBL1156391 0.76 KDM4E (0.43) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL3370448 0.75 MEN1 (0.48) MAPTSMN1; SMN2TP53PKMMEN1
SCHEMBL1156540 0.75 PKM (0.52) PKMMEN1KMT2AALDH1A1LMNA
SCHEMBL3368043 0.73 TUBB4A (0.44) MAPTSMN1; SMN2MEN1KMT2ACA12
SCHEMBL1156088 0.72 KDM4E (0.49) MAPTSMN1; SMN2CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1628957-B1 SULFOPYRROLES TAKEDA PHARMACEUTICAL (JP) 2010-09-29 EP disclosed
US-7612064-B2 Sulfopyrroles TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-03 US disclosed
US-20070060570-A1 Sulfopyrroles TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060570-A1 Sulfopyrroles TYK2, ARSA, SULT2A1 MAPT 4766/4885SMN1; SMN2 2378/4885TP53 2551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.